Posted by Michael Wonder on 03 Mar 2016

FDA approves new indication for Faslodex (fulvestrant)

Business Wire

2 March 2016 - The approval expands its use and offers additional option for women with HR+, HER2- metastatic breast cancer.

For more details, go to: http://www.businesswire.com/news/home/20160302006589/en/FDA-Approves-Indication-FASLODEX®-fulvestrant

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , US